Announcement
19.08.2011
The H1 interim report for NeuroSearch A/S (NEUR) will be released on 25 August 2011.
NeuroSearch will host a conference call on the same day at 3 pm CET (2 pm UK time, 9 am New York time) during which the H1 report will be presented. Participating in the call will be CEO Patrik Dahlen and EVP & CFO René Schneider.
The conference call will be conducted in English and the dial-in numbers are:
UK: +44 207 509 5139, the US: +1 718 354 1226, DK +45 3271 4767. The conference call can also be accessed via the company's website www.neurosearch.com.
The corresponding presentation will be available at the company's website just prior to the teleconference.
Contact person:
René Schneider, EVP & CFO, telephone: +45 4460 8700
About NeuroSearch
NeuroSearch is a European based biopharmaceutical company, listed on NASDAQ OMX Copenhagen A/S (NEUR) and specialising in CNS diseases. The company has a pipeline of specialty CNS drugs, including Huntexil® (pridopidine), a unique orphan drug in Phase III for the treatment of Huntington’s disease. NeuroSearch is building commercial competences with a view to commercialising Huntexil® through an in-house marketing and sales organisation.
NeuroSearch has a well-established drug discovery division, NsDiscovery, with unique capabilities in the field of ion channels and CNS diseases. The company has strategic drug discovery and development alliances with Janssen Pharmaceutica and Eli Lilly as well as a licence collaboration with Abbott. NeuroSearch also has equity interests in a number of unlisted companies in the Life Science industry.
